TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9572758

Group type: EXPERIMENTAL
Intervention: Secondary prevention clinics run by nurses in general practice
Number of subjects: 1173
Study: 9207310

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m2 intravenously once a week for 3 weeks (days 1, 8, and 15) followed by a 1-week rest period.
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 intravenously on day 1 of each 28-day cycle in combination with etoposide 100 mg/m2 on days 1, 2, and 3.
Number of subjects: 117
Study: 1742909

Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg i.v.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study: 6890840

Group type: EXPERIMENTAL
Intervention: Acetylsalicyclic acid (ASA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31999615

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 30782923

Group type: EXPERIMENTAL
Intervention: Advisory board and consultancies COI for gout review
Number of subjects: 749

Group type: COMPARATOR
Intervention: No COI for gout review
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Gout review
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Dyspepsia review
Number of subjects: 749
Study: 28142146

Group type: EXPERIMENTAL
Intervention: Surgical staging (arm A)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Clinical staging and primary chemoradiation (arm B)
Number of subjects: 234
Study: 25344881

Group type: EXPERIMENTAL
Intervention: SCPB (Superficial Cervical Plexus Block) with 10 ml 0.25% bupivacaine each side
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no SCPB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SCPB
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SCPB and Control groups
Number of subjects: 50
Study: 26404199

Group type: EXPERIMENTAL
Intervention: Ticagrelor 270 mg loading dose
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ticagrelor 360 mg loading dose
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ticagrelor 180 mg, 270 mg, 360 mg loading doses
Number of subjects: 52
Study: 23722481

Group type: EXPERIMENTAL
Intervention: Caffeinated 5-hour Energy shot
Number of subjects: 20

Group type: COMPARATOR
Intervention: Decaffeinated 5-hour Energy shot
Number of subjects: 20
Study: 22066355

Group type: EXPERIMENTAL
Intervention: Self-testing INR using CoaguChek (Roche) or INRatio (Hemosense) system (Group 2)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Conventional management with laboratory INR monitoring (Group 1)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Self-testing INR (Group 2)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Conventional management (Group 1)
Number of subjects: 206
Study: 19955065

Group type: EXPERIMENTAL
Intervention: Repair (n = 25)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sealing of defective margins (n = 12)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Refinishing (n = 19)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Replacement (n = 16)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No treatment (n = 16)
Number of subjects: 37
Study: 16341569

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (LGBP)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Laparoscopic adjustable silicone gastric banding (LASGB)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Both LGBP and LASGB
Number of subjects: 392
Study: 15486842

Group type: EXPERIMENTAL
Intervention: Telemedicine in the home
Number of subjects: 0
Study: 12575370

Group type: EXPERIMENTAL
Intervention: Tongyu No. I (TY‐1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Aspirin (control group)
Number of subjects: 62
Study: 10223211

Group type: EXPERIMENTAL
Intervention: Permethrin (200 mg/m2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Permethrin (500 mg/m2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lambdacyhalothrin (3 mg/m2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lambdacyhalothrin (15 mg/m2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 100
Study: 8272303

Group type: EXPERIMENTAL
Intervention: Higher-dose monophasic pill
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lower-dose monophasic pill
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multiphasic pill
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonsteroidal contraception
Number of subjects: 40
Study: 2679084

Group type: EXPERIMENTAL
Intervention: Simvastatin 5 to 10 mg once every afternoon (stratum I)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 to 20 mg once every afternoon (stratum II)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily (both strata)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Simvastatin 5 to 10 mg once every afternoon and gemfibrozil 600 mg twice daily
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 to 20 mg once every afternoon
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 290
Study: 1069556

Group type: EXPERIMENTAL
Intervention: BCG-cultured cell mixtures
Number of subjects: 62

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 62
Study: 31937617

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 46
Study: 23292649

Group type: EXPERIMENTAL
Intervention: IVUS assisted CAS
Number of subjects: 60

Group type: COMPARATOR
Intervention: CAS using angiography as the unique diagnostic tool
Number of subjects: 60
Study: 28629272

Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) + Treatment as Usual (TAU)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 12
Study: 26254792

Group type: EXPERIMENTAL
Intervention: CYP2D6*wt/*10 genotype
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CYP2D6*10/*10 genotype
Number of subjects: 62
Study: 23881680

Group type: EXPERIMENTAL
Intervention: Crystalline lysine (CLys)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Standardized ileal digestible (SID) Lys from SBM
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dietary Lys concentration increased
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pigs fed individually
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pigs fed CLys diets
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Gilts
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pigs fed individually with CLys
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Barrows fed individually
Number of subjects: 112
Study: 21764540

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 200

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 200
Study: 19906518

Group type: EXPERIMENTAL
Intervention: Cerebral GSH levels in myalgic encephalomyelitis patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal controls (age- and gender-matched)
Number of subjects: 26
Study: 17029618

Group type: COMPARATOR
Intervention: 40 tablets (60 g) of NaP
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: RF-NaP 40 tablets (60 g)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: RF-NaP 32 tablets (48 g)
Number of subjects: 816

Group type: COMPARATOR
Intervention: NaP
Number of subjects: 816
Study: 12767425

Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T(4)) replacement therapy for 6 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group of 14 euthyroid patients (52.5 +/- 10 years); thyroid-stimulating hormone 2.5 +/- 1.2 microUI/ml
Number of subjects: 10
Study: 11144687

Group type: EXPERIMENTAL
Intervention: Randomized trials in gynecologic oncology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informed consent process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocol review process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Publication of trial results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interim analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: International cooperation in trials
Number of subjects: 0
Study: 9425505

Group type: EXPERIMENTAL
Intervention: GnRH agonist and calcium, with or without nasal salmon calcitonin
Number of subjects: 40
Study: 8917031

Group type: EXPERIMENTAL
Intervention: 0.25% chlorhexidine gluconate, 0.025% benzalkonium chloride, and 4% benzyl alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10% povidone iodine
Number of subjects: 0
Study: 2808197

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate 666 mg tid
Number of subjects: 162

Group type: COMPARATOR
Intervention: Erythromycin base 500 mg qid
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate 400 mg qid
Number of subjects: 162
Study: 4604478

Group type: EXPERIMENTAL
Intervention: Whole-cell Inaba vaccine (2 annual injections)
Number of subjects: 45000

Group type: EXPERIMENTAL
Intervention: Purified Inaba vaccine (1 injection)
Number of subjects: 45000

Group type: EXPERIMENTAL
Intervention: Whole-cell Ogawa vaccine (2 annual injections)
Number of subjects: 45000

Group type: EXPERIMENTAL
Intervention: Ogawa vaccine
Number of subjects: 45000
Study: 31039755

Group type: EXPERIMENTAL
Intervention: One‐staged hybrid operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional operation
Number of subjects: 0
Study: 29240757

Group type: EXPERIMENTAL
Intervention: 10 session integrated cognitive behavioral therapy and HIV prevention intervention (n = 162)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Single session control (n = 153)
Number of subjects: 315
Study: 24604664

Group type: EXPERIMENTAL
Intervention: Dynamic inversion time (dynamic‐TI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Without dynamic inversion time
Number of subjects: 17
Study: 23428257

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (TSD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sleep condition
Number of subjects: 16
Study: 21494548

Group type: EXPERIMENTAL
Intervention: Intensive phase therapy for tuberculosis in African patients
Number of subjects: 328

Group type: COMPARATOR
Intervention: Intensive phase therapy for tuberculosis in non-African patients
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: African patients with the least disease severity
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: HIV infection, smoking, and diabetes
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Laboratory processing and culture procedures
Number of subjects: 328
Study: 19221370

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole (80 mg bolus followed by 8 mg/h infusion for 72 hours)
Number of subjects: 767
Study: 16530503

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2b monotherapy (1.5 microg/kg per week) started at week 8
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2b monotherapy (1.5 microg/kg per week) started at week 12
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2b monotherapy (1.5 microg/kg per week) started at week 20
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Overall treatment with peginterferon alfa‐2b
Number of subjects: 175
Study: 15108656

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 0
Study: 11128923

Group type: EXPERIMENTAL
Intervention: Collagen barrier
Number of subjects: 48

Group type: COMPARATOR
Intervention: ePTFE barrier
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both barriers
Number of subjects: 48
Study: 9301631

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin at night
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin twice a day
Number of subjects: 22
Study: 8408501

Group type: EXPERIMENTAL
Intervention: Oestrogen and progestin supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 30
Study: 3895810

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30257125

Group type: EXPERIMENTAL
Intervention: Zinc‐/copper‐containing welding fumes (2.5 mg/m3)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ambient air control
Number of subjects: 15
Study: 26562003

Group type: EXPERIMENTAL
Intervention: Head Massage Therapy (HMT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no HMT)
Number of subjects: 10
Study: 25267153

Group type: EXPERIMENTAL
Intervention: Advax 5mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Advax 10mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: HBsAg alone
Number of subjects: 16
Study: 22332874

Group type: EXPERIMENTAL
Intervention: Maternal T1D
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: In vitro insulin stimulation in infants with maternal T1D
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maternal T1D with PTPN22 allele
Number of subjects: 40

Group type: COMPARATOR
Intervention: Infants born to unaffected mothers
Number of subjects: 40
Study: 20504126

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurements
Number of subjects: 400

Group type: COMPARATOR
Intervention: Casual/Clinic Blood Pressure (CBP) measurements
Number of subjects: 400
Study: 18538113

Group type: COMPARATOR
Intervention: ZyrtecA (reference formulation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: RyvelA (test formulation)
Number of subjects: 18
Study: 16005554

Group type: EXPERIMENTAL
Intervention: Loaded condition (10% body mass)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unloaded condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recovery period (loaded)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recovery period (unloaded)
Number of subjects: 20
Study: 12464754

Group type: EXPERIMENTAL
Intervention: six telephone intervention sessions on safety behaviors
Number of subjects: 75

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 75
Study: 10351973

Group type: EXPERIMENTAL
Intervention: DRB1*0701 allele
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: DQA1*0201 allele
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: DRB1*0701-DQA1*0201 haplotype
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: DQA1*0103 allele
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: DQB1*0603 allele
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: DRB1*13-DQA1*0501-3-DQB1*0301 haplotype
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: DRB1*13-DQA1*0103-DQB1*0603 haplotype
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: MVD patients
Number of subjects: 88
Study: 8751234

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for 7 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 7 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Test meal
Number of subjects: 8
Study: 1726637

Group type: EXPERIMENTAL
Intervention: Alpha-blocker treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 6414271

Group type: EXPERIMENTAL
Intervention: Omnipaque, 300 mg l/ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amipaque, 300 mg l/ml
Number of subjects: 12
Study: 31022446

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 28174415

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 194

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 194
Study: 25658497

Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: SNRI/TCA
Number of subjects: 345
Study: 24356339

Group type: EXPERIMENTAL
Intervention: Lowest tertile of integrated DNA repair OMA score
Number of subjects: 192

Group type: COMPARATOR
Intervention: Highest tertile of integrated DNA repair OMA score
Number of subjects: 192
Study: 21919922

Group type: EXPERIMENTAL
Intervention: Prazosin (16 mg daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 19368417

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 320/9 microg
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 160/9 microg
Number of subjects: 1964

Group type: COMPARATOR
Intervention: Formoterol DPI 9 microg
Number of subjects: 1964

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1964
Study: 17404491

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activated vitamin D(3) analogues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin K(2) analogues
Number of subjects: 0
Study: 15039349

Group type: EXPERIMENTAL
Intervention: Vaccinated birds (DNA vaccine plasmid encoding the circumsporozoite protein of P. relictum)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Naïve birds
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vaccinated birds
Number of subjects: 3

Group type: COMPARATOR
Intervention: Cages of naïve birds
Number of subjects: 3
Study: 11174738

Group type: EXPERIMENTAL
Intervention: Duraflo II
Number of subjects: 1336

Group type: COMPARATOR
Intervention: Carmeda BioActive Surface
Number of subjects: 1336
Study: 9757855

Group type: EXPERIMENTAL
Intervention: Low-fat dairy products containing up to 1200 mg/d of calcium
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no increase in calcium intake)
Number of subjects: 70
Study: 8140876

Group type: EXPERIMENTAL
Intervention: Manual stimulation of needles (MS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electrical low frequency stimulation at 2 Hz (LF)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-frequency stimulation at 80 Hz (HF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 40
Study: 2903936

Group type: EXPERIMENTAL
Intervention: Benzodiazepine antagonist
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30208868

Group type: EXPERIMENTAL
Intervention: Individualized messages through an Interactive Voice Response (IVR) system
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Mother and Baby Affairs (MBA) workshops
Number of subjects: 795

Group type: COMPARATOR
Intervention: Standard leaflet with details on glucose testing and follow-up
Number of subjects: 795
Study: 27526661

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3048

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3048
Study: 26506383

Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g daily for six months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23021099

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study: 21383836

Group type: EXPERIMENTAL
Intervention: Descending piano melody exposure during the 35th, 36th, and 37th weeks of gestation, twice daily for 3 weeks.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ascending control piano melody.
Number of subjects: 50
Study: 18316340

Group type: EXPERIMENTAL
Intervention: Inadequate or unclear allocation concealment
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Lack of blinding
Number of subjects: 1346
Study: 16502765

Group type: EXPERIMENTAL
Intervention: High-fat fed (HFF)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-fat fed (LFF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fasting (reference)
Number of subjects: 45
Study: 15715403

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study: 10674956

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) 0.12% mouthrinse
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) combined with sodium perborate (CHX+PER)
Number of subjects: 28
Study: 9541360

Group type: EXPERIMENTAL
Intervention: Potassium iodate added to irrigation water (10-80 microg/l) for 2-4 weeks
Number of subjects: 37000
Study: 8309707

Group type: EXPERIMENTAL
Intervention: Cold stimulation of the teeth at varying temperatures from +30°C to ‐30°C
Number of subjects: 12
Study: 2880214

Group type: EXPERIMENTAL
Intervention: Intravenous glycerol (500 ml of a 10% solution in physiological saline)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Physiological saline (500 ml administered intravenously)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Intravenous glycerol
Number of subjects: 173
Study: 30069238

Group type: EXPERIMENTAL
Intervention: DEXA scan for diagnosing osteoporosis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DEXA scan
Number of subjects: 100
Study: 26925523

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 132
Study: 25557266

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 125

Group type: COMPARATOR
Intervention: Observation (Obs)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Second course of D+P
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 125
Study: 23852947

Group type: EXPERIMENTAL
Intervention: telbivudine
Number of subjects: 38

Group type: COMPARATOR
Intervention: lamivudine
Number of subjects: 38
Study: 20627916

Group type: EXPERIMENTAL
Intervention: Lung cancer screening
Number of subjects: 1284

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 1284
Study: 18261131

Group type: EXPERIMENTAL
Intervention: Risk magnitude 50%
Number of subjects: 180

Group type: COMPARATOR
Intervention: Risk magnitude 3%
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Risk provenance: mutation negative
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Grouped icon display
Number of subjects: 180

Group type: COMPARATOR
Intervention: Risk provenance: family history
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Risk magnitude 6%
Number of subjects: 180
Study: 16189256

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37